Sophia Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sophia Xiao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Allen Ni
Department of Pediatrics, and Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, MO, USA
1 shared publication Amir Ebadinejad
Department of Surgery University of Iowa Hospitals and Clinics Iowa City Iowa USA
1 shared publication- Ashrita Raghuram
Department of Neurology, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA
1 shared publication - Ethan Angle
Department of Surgery, University of Iowa Healthcare, Iowa City, IA, United States; Carver College of Medicine, University of Iowa, Iowa City, IA, United States
1 shared publication - Hassan Aziz
Department of Surgery University of Iowa Hospitals and Clinics Iowa City Iowa USA
1 shared publication - Ignacio Garcia Fleury
Department of Orthopedics and Rehabilitation University of Iowa Iowa City Iowa USA
1 shared publication
Latest Publications
- Open Access
- 6 August 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 830-839
Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors
Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs. Methods: ACS‐NSQIP (2019–2023) was queried for adult patients who underwent pancreatectomy for pNETs. Concurrent liver‐directed procedures were identified by CPT code and classified as hepatectomy or ablation alone; patients were grouped as isolated pancreatectomy, concurrent hepatectomy, or concurrent ablation alone. Pre‐, intra‐, and postoperative characteristics were compared using inferential statistics. Multivariable logistic regression identified predictors of 30‐day morbidity, readmission, reoperation, and mortality, with Firth penalized likelihood used for rare outcomes. Results: Of 4794 patients, 4587 (95.7%) underwent isolated pancreatectomy, 172 (3.6%) underwent concurrent hepatectomy, and 35 (0.7%) underwent concurrent ablation alone. Concurrent hepatectomy was parenchymal‐sparing in 163 of 172 patients (94.8%); only nine patients underwent a major hepatectomy. Overall morbidity was similar across groups (38.8%, 45.9%, and 42.9%; p = 0.154), as was serious morbidity (28.7%, 27.9%, 22.9%; p = 0.730) and 30‐day mortality (1.0%, 0.6%, 0%). On multivariable analysis, neither concurrent hepatectomy (OR 1.02, 95% CI 0.71–1.48) nor concurrent ablation (OR 0.94, 95% CI 0.46–1.93) was associated with morbidity. Pancreatoduodenectomy was associated with morbidity (OR 2.38, 95% CI 2.05–2.76), reoperation (OR 2.16, 95% CI 1.52–3.08), and mortality (OR 2.50, 95% CI 1.39–4.50), and a minimally invasive approach was associated with lower morbidity (OR 0.69, 95% CI 0.60–0.80). Conclusions: Concurrent liver‐directed surgery was not associated with an increase in 30‐day morbidity or mortality after pancreatectomy for pNETs. These findings support the safety of concurrent hepatic resection in appropriately selected pNET patients.
- 6 August 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 830-839
Open AccessPerioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors
Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs. Methods: ACS‐NSQIP (2019–2023) was queried for adult patients who underwent pancreatectomy for pNETs. Concurrent liver‐directed procedures were identified by CPT code and classified as hepatectomy or ablation alone; patients were grouped as isolated pancreatectomy, concurrent hepatectomy, or concurrent ablation alone. Pre‐, intra‐, and postoperative characteristics were compared using inferential statistics. Multivariable logistic regression identified predictors of 30‐day morbidity, readmission, reoperation, and mortality, with Firth penalized likelihood used for rare outcomes. Results: Of 4794 patients, 4587 (95.7%) underwent isolated pancreatectomy, 172 (3.6%) underwent concurrent hepatectomy, and 35 (0.7%) underwent concurrent ablation alone. Concurrent hepatectomy was parenchymal‐sparing in 163 of 172 patients (94.8%); only nine patients underwent a major hepatectomy. Overall morbidity was similar across groups (38.8%, 45.9%, and 42.9%; p = 0.154), as was serious morbidity (28.7%, 27.9%, 22.9%; p = 0.730) and 30‐day mortality (1.0%, 0.6%, 0%). On multivariable analysis, neither concurrent hepatectomy (OR 1.02, 95% CI 0.71–1.48) nor concurrent ablation (OR 0.94, 95% CI 0.46–1.93) was associated with morbidity. Pancreatoduodenectomy was associated with morbidity (OR 2.38, 95% CI 2.05–2.76), reoperation (OR 2.16, 95% CI 1.52–3.08), and mortality (OR 2.50, 95% CI 1.39–4.50), and a minimally invasive approach was associated with lower morbidity (OR 0.69, 95% CI 0.60–0.80). Conclusions: Concurrent liver‐directed surgery was not associated with an increase in 30‐day morbidity or mortality after pancreatectomy for pNETs. These findings support the safety of concurrent hepatic resection in appropriately selected pNET patients.
- Open Access
- 21 December 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (12) , e70180
Course of Carpal Tunnel Syndrome Management in Patients With Diabetes
Background: Carpal Tunnel Syndrome (CTS) is the most prevalent compressive neuropathy, often worsened by microvasculopathy in diabetic neuropathy. Diabetes mellitus (DM) patients experience increased CTS risk but are frequently underdiagnosed. This study investigates the progression to CTS diagnosis and CT release (CTR) in DM patients, aimed at better early detection and CTS prevention. Methods: Data including age and HbA1c from 304 patients with CTS, DM, and CTR (2012–2022) was collected from a tertiary care center. CTS–CTR time was compared between patients diagnosed with DM pre‐ or post‐CTS using Wilcoxon rank‐sum tests. Analyses were conducted using SAS v9.4. Relationships between age or HbA1c and CTS–CTR or DM–CTS timelines were described by Spearman correlation coefficients. Results: 51% ( n = 154) of patients received DM diagnosis post‐CTS identification. Time between diagnoses was similar in patients diagnosed with DM before vs. after CTS (24.6 (8.0–41.8), 24.3 (9.9–46.2) months, p = 0.604). From CTS to first CTR, the median time difference was 2.5 months (1.0–8.1) with no significant impact from DM diagnosis timing (before: 2.57, after: 2.20 months, p = 0.188). CTS–CTR time correlated with age ( = −0.24, p < 0.001) and HbA1c (=−0.15, p = 0.002) at CTS diagnosis. No associations occurred with age or HbA1c at DM diagnosis (age: = 0.03, p = 0.660, HbA1c: = 0.00, p = 1.00). Conclusions: Over half of CTR patients were diagnosed with DM before CTS, underscoring the urgency for assessing new DM patients for CTS symptoms. Future clinical programs should target early identification of CTS signs and optimal timing for surgical interventions to enhance patient well‐being.
- 21 December 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (12) , e70180
Open AccessCourse of Carpal Tunnel Syndrome Management in Patients With Diabetes
Background: Carpal Tunnel Syndrome (CTS) is the most prevalent compressive neuropathy, often worsened by microvasculopathy in diabetic neuropathy. Diabetes mellitus (DM) patients experience increased CTS risk but are frequently underdiagnosed. This study investigates the progression to CTS diagnosis and CT release (CTR) in DM patients, aimed at better early detection and CTS prevention. Methods: Data including age and HbA1c from 304 patients with CTS, DM, and CTR (2012–2022) was collected from a tertiary care center. CTS–CTR time was compared between patients diagnosed with DM pre‐ or post‐CTS using Wilcoxon rank‐sum tests. Analyses were conducted using SAS v9.4. Relationships between age or HbA1c and CTS–CTR or DM–CTS timelines were described by Spearman correlation coefficients. Results: 51% ( n = 154) of patients received DM diagnosis post‐CTS identification. Time between diagnoses was similar in patients diagnosed with DM before vs. after CTS (24.6 (8.0–41.8), 24.3 (9.9–46.2) months, p = 0.604). From CTS to first CTR, the median time difference was 2.5 months (1.0–8.1) with no significant impact from DM diagnosis timing (before: 2.57, after: 2.20 months, p = 0.188). CTS–CTR time correlated with age ( = −0.24, p < 0.001) and HbA1c (=−0.15, p = 0.002) at CTS diagnosis. No associations occurred with age or HbA1c at DM diagnosis (age: = 0.03, p = 0.660, HbA1c: = 0.00, p = 1.00). Conclusions: Over half of CTR patients were diagnosed with DM before CTS, underscoring the urgency for assessing new DM patients for CTS symptoms. Future clinical programs should target early identification of CTS signs and optimal timing for surgical interventions to enhance patient well‐being.
- 28 September 2023
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (6) , 1859-1874
Recombinant Erythropoietin Induces Oligodendrocyte Progenitor Cell Proliferation After Traumatic Brain Injury and Delayed Hypoxemia
- 28 September 2023
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (6) , 1859-1874
Recombinant Erythropoietin Induces Oligodendrocyte Progenitor Cell Proliferation After Traumatic Brain Injury and Delayed Hypoxemia